Skip to main content
Terug
Watch Compare

IGC Pharma, Inc.

Datakwaliteit: 100%
IGC
NYSE Manufacturing Chemicals
€ 0,30
▲ € 0,00 (0,03%)
Marktkapitalisatie: 28,20 M
Prijs
€ 0,29
Marktkapitalisatie
28,20 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -0,82% annually over 5 years
Debt/Equity of 0,02 — conservative balance sheet
Negative free cash flow of -5,49 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 34,57%
Capital efficient — spends only 2,70% of revenue on capex

Groei

Revenue Growth (5Y)
-0,82%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-35,39%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-48,99%
Boven sectorgemiddelde (-54,47%)
ROIC-91,75%
Net Margin-493,04%
Op. Margin-1192,19%

Veiligheid

Debt / Equity
0,02
Onder sectorgemiddelde (0,30)
Current Ratio1,32
Interest Coverage-2797,67

Waardering

PE (TTM)
-8,12
Onder sectorgemiddelde (-1,49)
P/B Ratio3,48
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -8,1 -1,5
P/B 3,5 1,6
ROE % -49,0 -54,5
Net Margin % -493,0 -41,5
Rev Growth 5Y % -0,8 1,8
D/E 0,0 0,3

Koersdoel Analisten

2 analisten
Buy
Huidig
€ 0,30
+1265.9%
Koersdoel
€ 4,13
€ 3,00
€ 4,13
€ 5,25
Vooruitzicht
Forward WPA -€ 0,09

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 — 0,0 —

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q32025 -€ 0,02 -€ 0,02 0,0%
Q22025 -€ 0,03 -€ 0,02 +20,0%
Q12025 -€ 0,02 -€ 0,01 +50,0%
Q42024 -€ 0,03 -€ 0,02 +33,3%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -35,39% Revenue Growth (3Y) -2,33%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -0,82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 704.000,0 Net Income (TTM) -3,47 M
ROE -48,99% ROA -39,25%
Gross Margin 26,85% Operating Margin -1192,19%
Net Margin -493,04% Free Cash Flow (TTM) -5,49 M
ROIC -91,75% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,02 Current Ratio 1,32
Interest Coverage -2797,67 Asset Turnover 0,08
Working Capital 490.000 Tangible Book Value 3,21 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -8,12 Forward P/E N/A
P/B Ratio 3,48 P/S Ratio 40,05
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -19,46%
Market Cap 28,20 M Enterprise Value 27,23 M
Per Share
EPS (Diluted TTM) -0,03 Revenue / Share 0,01
FCF / Share -0,06 OCF / Share -0,06
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2,70% FCF Conversion 158,11%
SBC-Adj. FCF -14,49 M Growth Momentum -34,57

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 869.000,0 1,35 M 911.000,0 397.000,0 898.000,0
Net Income -4,15 M -13,00 M -11,51 M -15,02 M -8,81 M
EPS (Diluted) -0,05 — — — —
Gross Profit 297.000,0 733.000,0 442.000,0 194.000,0 113.000,0
Operating Income -7,75 M -9,80 M -11,57 M -15,43 M -8,72 M
EBITDA — — — — —
R&D Expenses 3,92 M 3,77 M 3,46 M 2,33 M 929.000,0
SG&A Expenses 4,12 M 6,76 M 8,55 M 13,29 M 7,91 M
D&A 324.000,0 637.000,0 657.000,0 651.000,0 478.000,0
Interest Expense 4.000,0 5.000,0 5.000,0 5.000,0 3.000,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9,71 M 9,90 M 17,18 M 26,83 M 35,87 M
Total Liabilities 2,29 M 2,58 M 2,27 M 2,94 M 3,06 M
Shareholders' Equity 7,42 M 7,32 M 14,91 M 23,89 M 32,80 M
Total Debt 134.000,0 140.000,0 144.000,0 147.000,0 580.000,0
Cash & Equivalents 900.000,0 1,20 M 3,20 M 10,46 M 14,55 M
Current Assets 1,79 M 3,71 M 6,47 M 15,11 M 23,52 M
Current Liabilities 2,16 M 2,34 M 1,90 M 2,44 M 2,37 M